Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer

Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer

Background: Immunotherapy with ICIs has revolutionized the treatment for NSCLC. The impact of sex on treatment outcomes remains unclear. The aim of this study was to evaluate sex-related differences in immunotherapy outcomes in a real-world population of NSCLC patients. Methods: Demographics, clinic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sara Frida Cohen, Diane Cruiziat, Jeremy Naimer, Victor Cohen, Goulnar Kasymjanova, Alan Spatz, Jason Agulnik
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Current Oncology
Subjects:	mNSCLC immune checkpoint inhibitors (ICIs) sex-related differences
Online Access:	https://www.mdpi.com/1718-7729/31/11/544
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report
by: Yan Zhu, et al.
Published: (2024-11-01)

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer
by: Shaoqiu Chen, et al.
Published: (2024-11-01)

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
by: Jing Wei, et al.
Published: (2024-12-01)

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
by: Luigi Liguori, et al.
Published: (2024-11-01)

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01)

Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden
by: Hyungtai Sim, et al.
Published: (2024-12-01)

Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
by: Jacob New, et al.
Published: (2024-11-01)

A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China
by: Hongmei Li, et al.
Published: (2024-11-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
by: Yuhang Chen, et al.
Published: (2024-12-01)

Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function
by: Maor Tzuberi, et al.
Published: (2025-01-01)

Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
by: Emanuela Taioli, MD, PhD, et al.
Published: (2024-12-01)

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01)

Serum KL-6 levels reflect the severity of interstitial lung disease caused by immune checkpoint inhibitors
by: Xiaoping Li, et al.
Published: (2025-01-01)

The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis
by: Pedro C.A. Reis, et al.
Published: (2025-06-01)

The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature
by: Ido Amir, et al.
Published: (2024-06-01)

Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients
by: Alain Gelibter, et al.
Published: (2024-12-01)

Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
by: Yanxiong Mao, et al.
Published: (2024-11-01)

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
by: Xiaoye Shi, et al.
Published: (2024-12-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis
by: Shengfa Lin, et al.
Published: (2024-12-01)

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
by: Zheng Wang, et al.
Published: (2024-12-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications
by: Meshack Bida, et al.
Published: (2024-12-01)

Harnessing m1A modification: a new frontier in cancer immunotherapy
by: Xinru Wang, et al.
Published: (2024-12-01)

Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)
by: Iadalin Ryntathiang, et al.
Published: (2024-09-01)

Electrochemical sensors for the detection of immune checkpoint related proteins and their role in cancer companion diagnostics
by: Louise Barnaby, et al.
Published: (2025-03-01)

Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients
by: Annalisa Adamo, et al.
Published: (2023-12-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels
by: Fei Yang, et al.
Published: (2025-01-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Current advances in immunotherapy for cancer
by: Indrajit Desai, et al.
Published: (2024-12-01)

Sex differences in disease: sex chromosome and immunity
by: Zuxi Feng, et al.
Published: (2024-12-01)